Yes, obtain urgent compression ultrasound and bridge with therapeutic LMWH until INR is therapeutic
In a post-hip surgery patient restarted on warfarin who now presents with new calf symptoms, you should immediately obtain compression ultrasound to evaluate for DVT and initiate therapeutic-dose LMWH bridging until the INR reaches therapeutic range. This approach addresses the critical gap period when warfarin has been restarted but has not yet achieved anticoagulant effect, leaving the patient vulnerable to thrombotic complications.
Rationale for Bridging in This Clinical Scenario
The patient faces dual high-risk factors: recent major orthopedic surgery (hip surgery) and an indication for chronic anticoagulation. Hip surgery carries substantial VTE risk, and the immediate postoperative period represents peak thrombotic vulnerability 1, 2.
Why Warfarin Alone Is Insufficient
Warfarin requires 4-5 days to achieve therapeutic anticoagulation even when restarted immediately postoperatively 3, 4. The FDA label explicitly states that "the anticoagulant effect of warfarin is delayed" and recommends overlapping with heparin for 4-5 days until therapeutic PT/INR is achieved 4. During this lag period, the patient remains essentially unprotected against thrombosis despite taking warfarin.
The Evidence for Therapeutic Bridging
Therapeutic-dose LMWH bridging is specifically recommended when warfarin is restarted postoperatively until INR returns to therapeutic levels 3. The 2009 European Heart Journal guidelines state that "LMWH or UFH should be continued until the INR returns to therapeutic levels" 3. The 2026 ACC/AHA guidelines similarly recommend resuming postoperative LMWH bridge "until INR is within therapeutic range" in appropriate patients 1.
Specific Management Protocol
Immediate Actions
Order urgent bilateral lower extremity compression ultrasound to evaluate the calf symptoms
- Do not delay imaging while waiting for INR results
- New calf symptoms post-hip surgery warrant immediate DVT evaluation 5
Check current INR to determine anticoagulation status
- If INR < 2.0 (highly likely if warfarin just restarted), therapeutic bridging is indicated
LMWH Bridging Dosing
Initiate therapeutic-dose LMWH immediately if ultrasound confirms DVT or while awaiting results if clinical suspicion is high:
- Enoxaparin 1 mg/kg subcutaneously every 12 hours, OR
- Dalteparin 100 IU/kg subcutaneously every 12 hours 3, 2, 6
Dose based on actual body weight, not capped doses, even in obese patients 7.
Timing Considerations
The guidelines specify that postoperative LMWH should be restarted 12-24 hours after hip surgery once adequate hemostasis is established 3, 8, 2. If the patient was restarted on warfarin "immediately postop" without bridging, this represents a management gap that needs correction now.
Duration of Bridging
Continue therapeutic LMWH until INR is therapeutic (≥2.0) for at least 24-48 hours 3, 9, 8. This typically requires:
- Daily INR monitoring during overlap period
- Minimum 4-5 days of overlap therapy 4
- Two consecutive therapeutic INR readings before discontinuing LMWH 9
Risk Stratification Context
This patient likely falls into high thrombotic risk category based on:
- Recent major orthopedic surgery (hip surgery = high VTE risk)
- Requirement for chronic anticoagulation (underlying indication)
- New symptoms suggesting possible DVT
The 2022 ACCP guidelines classify recent VTE (<1-3 months) and active cancer as high-risk conditions warranting bridging 2. While the specific underlying indication for warfarin isn't stated, the combination of major orthopedic surgery plus chronic anticoagulation need plus new calf symptoms creates a high-risk scenario.
Common Pitfalls to Avoid
Don't Use Prophylactic-Dose LMWH
Some guidelines suggest starting with prophylactic doses postoperatively then escalating 8, but in a patient with suspected DVT or confirmed high thrombotic risk, therapeutic dosing is required from the start 3, 2.
Don't Delay LMWH Pending Ultrasound Results
If clinical suspicion for DVT is moderate-to-high based on calf symptoms, initiate therapeutic LMWH while awaiting imaging 2. The risk of untreated DVT progression or PE outweighs the bleeding risk in this setting.
Don't Assume Warfarin Provides Immediate Protection
A critical error is believing that restarting warfarin immediately postop provides anticoagulation. Warfarin takes 4-5 days minimum to achieve therapeutic effect 4, and during this window the patient remains at full thrombotic risk.
Monitor for Bleeding
Recent hip surgery creates elevated bleeding risk. The 2026 study found 16% bleeding incidence during dual warfarin-LMWH therapy, with 23.9% in postoperative patients 10. However, most bleeding was minor and managed in the community. The key is:
- Assess surgical site hemostasis before starting therapeutic LMWH
- Monitor for bleeding signs
- Balance thrombotic risk (which is very high with suspected DVT) against bleeding risk
Renal Function Consideration
Check renal function before dosing LMWH 2, 11. If creatinine clearance <30 mL/min, consider:
Alternative Scenario: If No DVT Found
If ultrasound is negative for DVT, the decision becomes more nuanced:
If patient has high baseline thrombotic risk (mechanical heart valve, recent VTE <3 months, CHADS₂ ≥3): Continue therapeutic LMWH bridging until INR therapeutic 8
If patient has low-moderate baseline thrombotic risk: May use prophylactic-dose LMWH or continue warfarin alone, depending on specific indication 1, 2
However, given that this patient had hip surgery (inherently high VTE risk) and is on chronic anticoagulation, therapeutic bridging is likely warranted regardless.
Key Takeaway
The combination of recent hip surgery, chronic anticoagulation indication, newly restarted warfarin (not yet therapeutic), and new calf symptoms creates a high-risk scenario requiring aggressive management. Obtain urgent imaging and initiate therapeutic LMWH bridging without delay. The evidence consistently supports bridging therapy when warfarin is restarted postoperatively until therapeutic INR is achieved, particularly in high-risk patients 3, 1, 8, 2.